FAAH Inhibitor Trial for Adults With Tourette Syndrome

Inclusion Criteria:

- Adult between 18-60 years of age

- Meet DSM IV criteria for the diagnosis of Tourette's syndrome

- Significant current tic symptoms: YGTSS total tic score greater than or equal to 22 at
baseline

- On stable psychiatric medication regimen for a minimum of 4 weeks prior to beginning
the trial.

- Accepted method of birth control

Exclusion Criteria:

- Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental
disorder or intellectual disability (IQ<70).

- Current use of medications that have significant effects on the cannabinoid or
dopamine systems. Subjects will be specifically excluded for recent use (within last 8
weeks) of antipsychotic medications, dopamine agonists or psychostimulants.

- Recent change (less than 4 weeks) in other medications that have potential effects on
tic severity (such as alpha-2 agonists (guanfacine, clonidine or prazosin), SSRIs,
clomipramine, naltrexone, lithium, anxiolytics, topiramate, baclofen etc.). Medication
change is defined to include dose changes or medication discontinuation.

- Recent change in behavioral treatment for Tourette syndrome or comorbid conditions
(i.e. OCD) within the last 4 weeks or initiation of behavioral therapy for tics within
the last 12 weeks.

- Positive pregnancy test or drug screening test

- History of cannabis dependence

- Significant Medical Comorbidity